# Embios

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/embios

- Headquarters: Beijing, China
- Latest round: Series A (Dec 8, 2025)
- Investors on record: 6

## About

Based in Beijing, China and established in 2022, Embios was founded by Professor Qi Hai’s team from Tsinghua University School of Medicine. The company aims to translate foundational research in humoral immunity into therapeutic products addressing immune dysfunction in acquired immune diseases. Its first candidate has shown promising preclinical results in systemic lupus erythematosus, rheumatoid arthritis and Sjögren’s syndrome. In December 2025, Embios raised an undisclosed amount in series A funding led by new investor Cathay Capital, with participation from other new investor Guokai Kechuang. Returning investor Qiming Venture Partners also participated in the round. The company develops monoclonal antibodies and antibody-drug conjugates targeting upstream and downstream regulators of immune memory and inflammatory responses. The company plans to generate revenue through the licensing of its antibody and ADC drug candidates and through the sales of drugs distribution. The company plans to submit IND applications for its lead candidate in both China and the US by the end of 2025 and expand its pipeline targeting immune and inflammatory diseases.

## Funding rounds

- Series A, Dec 8, 2025 — Qiming Venture Partners, Cathay Capital, Guokai Kechuang
- Angel, May 5, 2022 — Qiming Venture Partners, Lotus Lake Capital, Tsinghua Holdings, Bohe Angel Fund

## Investors

- Qiming Venture Partners (https://capitalatlas.ai/funds/qiming-venture-partners) — Angel, Series A
- Lotus Lake Capital (https://capitalatlas.ai/funds/lotus-lake-capital) — Angel
- Tsinghua Holdings — Angel
- Bohe Angel Fund — Angel
- Cathay Capital — Series A
- Guokai Kechuang — Series A